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Background: Probiotics may have beneficial effect in reducing adverse events in patients 
treated for Helicobacter (H.) pylori infection; however, data on their use in this setting are 
scarce. 
Aim: To investigate the use of probiotic supplementation in the treatment 
of H. pylori infection in clinical practice in Italy. 
Methods: The “Italian Registry on H. pylori treatment” is an online database prospectively 
registering adult patients prescribed with a treatment for H. pylori infection by 
gastroenterologists in Italy. Data were collected in 17 Centers from June 2017 to May 
2019 using the web application REDCap (Research Electronic Data Capture). 
Results: A total of 1803 patients [1140 (63.5%) females, mean age (SD): 55.4 years 
(15.1)] were included in the Registry in the study period. Of these, 1699 received one 
treatment regimen, 101 two regimens and 3 three regimens, with a total of 1910 cases. 
Probiotics were prescribed in 49.9% (n. 953) of cases: 100% (61/61) with rifabutin triple 
therapy, 86.4% (472/546) with sequential therapy, 54.2% (77/142) with levofloxacin triple 
therapy, 46.3% (38/82) with concomitant therapy, 33% (211/641) with bismuth quadruple 
therapy (Pylera®), 24.1% (90/374) with clarithromycin triple therapy and 21.1% (4/19) with 
other regimens. The most frequently prescribed probiotic was a combination 
of Lactobacillus rhamnosus and Bifidobacterium breve (586, 61.5%), followed 
by Lactobacillus casei DG (118, 12.4%), Lactobacillus rhamnosus (85, 
8.9%), Saccaromyces boulardii (74, 7.8%) and others probiotics (90, 9.4%). Conclusions 
Probiotic supplementation is used in half of patients treated for H. pylori eradication in 
Italy. Lactobacillus and Bifidobacterium are the probiotics most commonly prescribed. 
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